Welcome to our dedicated page for Enliven Therapeutics SEC filings (Ticker: ELVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enliven Therapeutics SEC filings document a clinical-stage biopharmaceutical issuer developing small-molecule therapeutics, with disclosures centered on ELVN-001 for chronic myeloid leukemia and related operating results and cash resources. Current reports furnish quarterly and annual financial results and attach business updates describing ENABLE clinical-trial activity, regulatory-development topics, and program plans.
Proxy and governance filings describe annual meeting matters, board composition, committee leadership, executive transitions, director compensation, equity awards, and stockholder voting procedures. The filings also identify Enliven common stock on the Nasdaq Global Select Market and record material-event amendments when furnished press-release exhibits are corrected.
Enliven Therapeutics, Inc. director Lori Anne Kunkel reported selling a total of 10,000 shares of common stock in open-market transactions on July 6, 2026. The sales were executed at weighted average prices of $50.8442 and $49.9834 per share.
According to a footnote, these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026, indicating the sales were scheduled in advance rather than timed discretionarily.
Enliven Therapeutics, Inc. reported that investment entities affiliated with OrbiMed executed open-market sales of its Common Stock. On June 22, 2026, the entities sold a combined 860,123 shares of Enliven at prices around $45–$45.38 per share.
After these transactions, one OrbiMed-affiliated fund reported 6,601,878 shares of Enliven Common Stock indirectly owned, while another reported 220,882 shares. The OrbiMed reporting entities and their related general partners and adviser disclaim beneficial ownership of the securities beyond any pecuniary interest.
OrbiMed Advisors LLC and affiliated entities filed Amendment No. 5 to their Schedule 13D on Enliven Therapeutics, Inc., reporting a reduction in beneficial ownership. They now report beneficial ownership of 6,774,507 Enliven common Shares, representing 9.5% of the 71,422,989 Shares outstanding as set out in the issuer’s June 12, 2026 Rule 424(b)(5) prospectus.
OPI VII holds 6,555,102 Shares, or about 9.2% of the class, while Genesis holds 219,405 Shares, or about 0.3%. On June 22, 2025, these funds and BIOG executed multiple open‑market sales at prices of $45.38 and $45.00 per Share. The filing states that the reporting persons may buy or sell additional Shares over time depending on market conditions and other factors but do not currently have specific plans for corporate control or strategic actions at the issuer.
ELVN affiliates reported proposed sales of Common Stock under Form 144, with broker-handled orders and a recent resale by a fund. Examples include OrbiMed Genesis Master Fund selling 9,086 shares on 06/15/2026 and broker entries showing 24,846 shares (Jefferies LLC). Shares outstanding were 69,822,989 as of 06/22/2026.
The filing lists broker participants and an earlier issuer-related line dated 02/23/2023 showing 26,323 shares. The notice documents proposed and recent transactions; timing and proceeds mechanics follow the sale notices provided.
ELVN notice of proposed sale of Common Stock under Rule 144 by selling holders, reporting broker allocations and recent dispositions.
The filing lists a proposed sale of 833,800 shares (dated 02/23/2023), broker entries showing 787,024 and 46,776 shares, and a recent reported sale of 272,322 shares on 06/15/2026 for $12,259,936.44. The excerpt shows total shares outstanding as 69,822,989 as of 06/22/2026.
The Biotech Growth Trust PLC reported proposed sales of Common Stock under a Form 144. The filing lists proposed brokered sales of 29,385 shares through Jefferies LLC and 1,747 shares through Morgan Stanley & Co. LLC. The filing also records a prior sale of 10,243 shares on 06/15/2026 for $461,139.86. Shares outstanding are shown as 69,822,989 as of 06/22/2026.
Enliven Therapeutics, Inc. chief financial officer Benjamin Hohl exercised stock options and sold shares of common stock in coordinated transactions. He exercised options for 6,018 shares at an exercise price of $2.48 per share and then sold 6,018 shares in several open-market trades on June 17, 2026 at weighted average prices between $42.79 and $44.75 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. Following the transactions, Hohl directly holds 51,000 shares of Enliven common stock, indicating he retains a meaningful equity stake in the company.
Enliven Therapeutics, Inc. chief medical officer Helen Louise Collins reported a mix of option exercise and share sales in the company’s stock. On June 17, 2026, she exercised options for 5,000 shares of common stock at a strike price of $2.48 per share, then sold a total of 5,000 shares in three open-market transactions at weighted average prices of $42.8270, $43.8701 and $44.7430 per share. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 19, 2025. Following the transactions, she holds 30,000 shares of common stock directly and 121,268 stock options.
Enliven Therapeutics disclosed that Polar Capital entities beneficially own 5,056,807 shares of Common Stock, representing 8.46% of the class. The filing cites 60,904,946 shares outstanding as reported in the issuer's Form 10-Q on May 7, 2026. The Schedule 13G/A is signed on June 19, 2026 by Nicholas Farren.
Enliven Therapeutics, Inc. disclosed that investment entities affiliated with OrbiMed executed open-market sales of its Common Stock. OrbiMed-related holders sold 272,322 shares at $45.02 per share and an additional 9,086 shares at the same price. After these transactions, the reporting entities’ indirect holdings reported in this filing were 7,388,902 shares and 245,728 shares, respectively. Footnotes explain that OrbiMed Genesis Master Fund, L.P. and OrbiMed Private Investments VII, LP hold the shares of record, and OrbiMed-affiliated general partners and OrbiMed Advisors may be deemed to share voting and investment power while disclaiming beneficial ownership beyond any pecuniary interest.